Publications 2020

Ascierto PA, Del Vecchio M, Mackiewicz A, Robert C, Chiarion-Sileni V, Arance A, Lebbé C, Svane IM, McNeil C, Rutkowski P, Loquai C, Mortier L, Hamid O, Bastholt L, Dreno B, Schadendorf D, Garbe C, Nyakas M, Grob JJ, Thomas L, Liszkay G, Smylie M, Hoeller C, Ferraresi V, Grange F et al. (2020)
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
J Immunother Cancer, 8 (1)
DOI 10.1136/jitc-2019-000391, PubMed 32503946

Bhave P, Pallan L, Long GV, Menzies AM, Atkinson V, Cohen JV, Sullivan RJ, Chiarion-Sileni V, Nyakas M, Kahler K, Hauschild A, Plummer R, Trojaniello C, Ascierto PA, Zimmer L, Schadendorf D, Allayous C, Lebbe C, Maurichi A, Santinami M, Roy S, Robert C, Lesimple T, Patel S, Versluis JM et al. (2020)
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
Br J Cancer
DOI 10.1038/s41416-020-01121-y, PubMed 33087895

Brunsvig PF, Guren TK, Nyakas M, Steinfeldt-Reisse CH, Rasch W, Kyte JA, Juul HV, Aamdal S, Gaudernack G, Inderberg EM (2020)
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
Front Immunol, 11, 572172
DOI 10.3389/fimmu.2020.572172, PubMed 33324397

Dummer R, Hauschild A, Santinami M, Atkinson V, Mandalà M, Kirkwood JM, Chiarion Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Gasal E, Tan M, Long GV, Schadendorf D (2020)
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
N Engl J Med, 383 (12), 1139-1148
DOI 10.1056/NEJMoa2005493, PubMed 32877599

Flem-Karlsen K, Nyakas M, Farstad IN, McFadden E, Wernhoff P, Jacobsen KD, Flørenes VA, Mælandsmo GM (2020)
Soluble AXL as a marker of disease progression and survival in melanoma
PLoS One, 15 (1), e0227187
DOI 10.1371/journal.pone.0227187, PubMed 31917795

Ny L, Hernberg M, Nyakas M, Koivunen J, Oddershede L, Yoon M, Wang X, Guyot P, Geisler J (2020)
BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis
Acta Oncol, 59 (7), 833-844
DOI 10.1080/0284186X.2020.1747636, PubMed 32285732

Puzanov I, Ribas A, Robert C, Schachter J, Nyakas M, Daud A, Arance A, Carlino MS, O'Day SJ, Long GV, Margolin KA, Dummer R, Schadendorf D, Lutzky J, Ascierto PA, Tarhini A, Lin J, Mogg R, Homet Moreno B, Ibrahim N, Hamid O (2020)
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials
JAMA Oncol, 6 (8), 1256-1264
DOI 10.1001/jamaoncol.2020.2288, PubMed 32672795

Publications 2019

Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejberg L, Schmidt H, van Thienen JV, Haanen JBAG, Tiainen L, Svane IM, Mäkelä S, Seremet T, Arance A, Dummer R, Bastholt L, Nyakas M, Straume O, Menzies AM, Long GV, Atkinson V, Blank CU, Neyns B (2019)
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
Ann Oncol, 30 (7), 1154-1161
DOI 10.1093/annonc/mdz110, PubMed 30923820

Long GV, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Hauschild A (2019)
Reply to E. Hindié and K.R. Hess
J Clin Oncol, 37 (15), 1356-1358
DOI 10.1200/JCO.19.00004, PubMed 30939092

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848

Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Lesimple T, Plummer R, Schachter J, Dasgupta K, Manson S, Koruth R, Mookerjee B, Kefford R, Dummer R, Kirkwood JM, Long GV (2019)
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF^V600E or BRAF^V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Lancet Oncol, 20 (5), 701-710
DOI 10.1016/S1470-2045(18)30940-9, PubMed 30928620

Publications 2018

Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, Hoeller C, Bar-Sela G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A (2018)
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
Eur J Cancer, 101, 236-243
DOI 10.1016/j.ejca.2018.06.034, PubMed 30096704

Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Long GV (2018)
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma
J Clin Oncol, 36 (35), 3441-3449
DOI 10.1200/JCO.18.01219, PubMed 30343620

Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Vecchio MD, Ascierto PA, Krajsová I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandalà M, Gogas H, Espinosa E, Hospers G, Lorigan P, Nyakas M, Guminski A, Liszkay G, Rutkowski P, Miller W, Donica M, Makrutzki M, Blank C (2018)
An open-label, multicentre safety study of vemurafenib in patients with BRAF^V600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system
Eur J Cancer, 107, 175-185
DOI 10.1016/j.ejca.2018.11.018, PubMed 30580112

Publications 2017

Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, Lebbé C, Bastholt L, Hamid O, Rutkowski P, McNeil C, Garbe C, Loquai C, Dreno B, Thomas L, Grob JJ, Liszkay G, Nyakas M, Gutzmer R, Pikiel J, Grange F, Hoeller C, Ferraresi V, Smylie M, Schadendorf D et al. (2017)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Lancet Oncol, 18 (5), 611-622
DOI 10.1016/S1470-2045(17)30231-0, PubMed 28359784

Delord JP, Robert C, Nyakas M, McArthur GA, Kudchakar R, Mahipal A, Yamada Y, Sullivan R, Arance A, Kefford RF, Carlino MS, Hidalgo M, Gomez-Roca C, Michel D, Seroutou A, Aslanis V, Caponigro G, Stuart DD, Moutouh-de Parseval L, Demuth T, Dummer R (2017)
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma
Clin Cancer Res, 23 (18), 5339-5348
DOI 10.1158/1078-0432.CCR-16-2923, PubMed 28611198

Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
N Engl J Med, 377 (19), 1813-1823
DOI 10.1056/NEJMoa1708539, PubMed 28891408

Publications 2016

Sioud M, Nyakas M, Sæbøe-Larssen S, Mobergslien A, Aamdal S, Kvalheim G (2016)
Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine
Case Rep Med, 2016, 9639585
DOI 10.1155/2016/9639585, PubMed 27504122

Publications 2013

Cohen RB, Aamdal S, Nyakas M, Cavallin M, Green D, Learoyd M, Smith I, Kurzrock R (2013)
A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies
Eur J Cancer, 49 (7), 1521-9
DOI 10.1016/j.ejca.2013.01.013, PubMed 23433846

Geisler J, Bachmann IM, Nyakas M, Helsing P, Fjøsne HE, Mæhle LO, Aamdal S, Eide NA, Svendsen HL, Straume O, Robsahm TE, Jacobsen KD, Akslen LA (2013)
Malignant melanoma--diagnosis, treatment and follow-up in Norway
Tidsskr Nor Laegeforen, 133 (20), 2154-9
DOI 10.4045/tidsskr.12.1416, PubMed 24172628

Robert C, Dummer R, Gutzmer R, Lorigan P, Kim KB, Nyakas M, Arance A, Liszkay G, Schadendorf D, Cantarini M, Spencer S, Middleton MR (2013)
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
Lancet Oncol, 14 (8), 733-40
DOI 10.1016/S1470-2045(13)70237-7, PubMed 23735514

Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, Suso EM, Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, Rasmussen AM, Lote K, Aamdal S, Gaudernack G, Kvalheim G, Langmoen IA (2013)
Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
Cancer Immunol Immunother, 62 (9), 1499-509
DOI 10.1007/s00262-013-1453-3, PubMed 23817721

Publications 2012

Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D et al. (2012)
Improved survival with MEK inhibition in BRAF-mutated melanoma
N Engl J Med, 367 (2), 107-14
DOI 10.1056/NEJMoa1203421, PubMed 22663011

Kaye S, Aamdal S, Jones R, Freyer G, Pujade-Lauraine E, de Vries EG, Barriuso J, Sandhu S, Tan DS, Hartog V, Kuenen B, Ruijter R, Kristensen GB, Nyakas M, Barrett S, Burke W, Pietersma D, Stuart M, Emeribe U, Boven E (2012)
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
Br J Cancer, 106 (11), 1728-34
DOI 10.1038/bjc.2012.158, PubMed 22531637

Publications 2011

Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S (2011)
Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial
Clin Cancer Res, 17 (21), 6847-57
DOI 10.1158/1078-0432.CCR-11-1385, PubMed 21918169